Cargando…
Reviving oncogenic addiction to MET bypassed by BRAF (G469A) mutation
Cancer clonal evolution is based on accrual of driving genetic alterations that are expected to cooperate and progressively increase malignancy. Little is known on whether any genetic alteration can hinder the oncogenic function of a coexisting alteration, so that therapeutic targeting of the one ca...
Autores principales: | Virzì, Anna Rita, Gentile, Alessandra, Benvenuti, Silvia, Comoglio, Paolo M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6176587/ https://www.ncbi.nlm.nih.gov/pubmed/30224486 http://dx.doi.org/10.1073/pnas.1721147115 |
Ejemplares similares
-
ROR1 is a pseudokinase that is crucial for MET-driven tumorigenesis
por: Lazzari, Luca, et al.
Publicado: (2013) -
MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin
por: Stella, Giulia M., et al.
Publicado: (2017) -
The relevance of BRAF G469A mutation in determining the response to therapy in metastatic melanoma
por: Porcelli, Letizia, et al.
Publicado: (2015) -
An Observatory for the MET Oncogene: A Guide for Targeted Therapies
por: Altintas, Dogus M., et al.
Publicado: (2023) -
MET Oncogene Controls Invasive Growth by Coupling with NMDA Receptor
por: Gallo, Simona, et al.
Publicado: (2022)